查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370900

生物相似藥單株抗體市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、按應用、地區、競爭細分。

Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Application, By Region, By Competition.
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球生物相似藥單株抗體（mAb）市值為52.2億美元，預計在預測期內將大幅成長，預計到2028年年複合成長率為11.87%，預計到2028年將達到101.9億美元。抗體（mAb）市場已成為生物製藥行業中一個充滿活力和變革的領域。生物相似藥通常被稱為生物藥物的「學名藥」版本，因其在保持可比較的安全性和有效性的同時為昂貴的生物製劑提供具有成本效益的替代品的潛力而受到廣泛關注。近年來，單株抗體生物相似藥取得了顯著的進步，重塑了製藥格局，並為改善患者的可及性和醫療保健的可負擔性打開了大門。單株抗體是一類生物藥物，旨在針對體內特定的蛋白質、細胞或組織。事實證明，它們在治療多種疾病方面非常有效，包括癌症、自體免疫疾病和發炎。然而，單株抗體的複雜性和複雜的製造過程導致了高昂的開發成本以及隨後增加的治療費用。生物相似藥 mAb 本質上與已批准的參考 mAb 高度相似，採用重組 DNA 技術開發並在活細胞中製造。雖然由於生物製劑固有的變異性，它們可能與參考產品不同，但它們的設計在安全性、有效性和品質方面盡可能接近。主要促進因素之一是全球醫療保健系統內迫切需要控制成本。生物相似藥單株抗體具有顯著減少醫療保健支出的潛力，因為與參考產品相比，它們通常以較低的價格進入市場，從而增強了市場的預期成長。

主要市場促進因素

癌症和自體免疫疾病的增加推動了生物相似藥單株抗體市場

市場概況
預測期 2024-2028
2022 年市場規模 52.2億美元
2028 年市場規模 101.9億美元
2023-2028 年年複合成長率 11.87%
成長最快的細分市場 腫瘤學
最大的市場 亞太地區

醫療保健領域見證了癌症和自體免疫疾病的盛行率大幅上升，這些複雜且具挑戰性的醫療狀況影響著全世界數百萬人。隨著這些疾病的發生率持續上升，對有效且負擔得起的治療方法的需求導致了生物相似藥單株抗體（mAb）市場的出現和擴張。這個快速發展的細分市場在滿足患者的治療需求方面發揮關鍵作用，同時為醫療保健系統提供潛在的成本節約。癌症和自體免疫疾病代表了兩種不同的醫學挑戰，兩者的特徵都是涉及免疫系統的複雜機制。癌症是一組以不受控制的細胞生長為特徵的疾病，也是全球主要死亡原因之一。另一方面，自體免疫疾病是由錯誤的免疫反應引起的，即人體的免疫系統攻擊自身的健康組織，導致慢性發炎和組織損傷。在過去的幾十年裡，由於人口老化、環境暴露、生活方式的改變和遺傳傾向的推動，癌症和自體免疫疾病的發生率一直在穩步上升。因此，迫切需要創新且有效的療法來治療這些疾病並改善患者的生活品質。由於對癌症和自體免疫疾病更實惠的治療方案的需求不斷增加，生物相似藥單株抗體市場迅速成長。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構已製定生物相似藥核准指南和途徑，確保對其安全性和有效性進行嚴格評估。

不斷增加的監管支持推動生物相似藥單株抗體市場

為了解決對生物相似藥單株抗體的安全性、有效性和品質的擔憂，世界各地的監管機構制定了全面的指南和框架。這些指南概述了生物相似藥產品在批准進入市場之前必須經過的嚴格的科學和臨床評估流程。目標是確保患者和醫療保健專業人員可以相信生物相似藥與其參考產品的等效性。例如，歐洲藥品管理局 (EMA) 和美國食品藥物管理局 (FDA) 都發布了針對生物相似藥單株抗體的指南。這些指南強調廣泛的比較分析研究，包括物理化學和功能表徵，以及非臨床和臨床研究，以證明與參考產品的等效性。隨著更多原廠單株抗體專利到期，生物相似藥替代品的市場已經成熟。這為製造商進入市場並以有競爭力的價格提供替代品創造了機會。 EMA 和 FDA 等機構制定的嚴格監管途徑和指南增強了醫療保健專業人員和患者對生物相似藥單株抗體安全性和有效性的信心。

主要市場挑戰

製造複雜性

單株抗體生物相似藥的製造過程非常複雜，並且涉及活細胞，這可能會導致產品的變異性。保持與參考產品一致的品質和可比性是一項重大挑戰。

臨床試驗和數據要求

產生證明生物相似藥及其參考單株抗體之間安全性和有效性相似性的臨床試驗資料對於監管部門的批准至關重要。設計這些試驗並確保患者招募可能非常複雜且耗費資源。

市場競爭

隨著越來越多的公司進入單株抗體生物相似藥市場，競爭加劇。定價策略、市場進入和差異化成為成功的關鍵因素。

主要市場趨勢

技術進步

近年來，在生物技術和創新研究方法的顯著進步的推動下，製藥業經歷了巨大的轉變。在這些重大突破中，生物相似藥單株抗體 (mAb) 已成為塑造醫學格局的強大力量。這些尖端治療藥物正在徹底改變從癌症到自體免疫疾病等各種疾病的治療。單株抗體生物相似藥市場的快速成長與技術和創新的不斷進步錯綜複雜地交織在一起。科技的進步使人們能夠更深入地了解疾病機制和患者變異性。這為精準醫學的概念鋪平了道路，即根據患者的基因組成、疾病特徵和對治療的反應，為個別患者量身定做治療方法。生物相似藥單株抗體在這方面具有巨大的前景，因為它們可以被開發為更精確地針對特定疾病途徑。這種方法不僅可以提高治療效果，還可以最大限度地減少副作用，從而提高患者的生活品質。生物相似藥單株抗體市場成長的關鍵驅動力之一是生物加工和製造技術的不斷發展。細胞培養技術、純化製程和生物反應器設計方面的創新使製造商能夠生產具有更高純度和產量的生物相似藥單株抗體。這不僅確保了最終產品的安全性，而且還降低了生產成本，使這些療法對於患者和醫療保健系統來說更加經濟可行。生物相似藥單株抗體與其參考產品的準確表徵和比較對於確保其安全性和有效性至關重要。質譜、核磁共振和高效液相層析等分析技術的進步使得全面評估生物相似藥和參考單株抗體之間的結構和功能相似性成為可能。這種詳細程度對於監管部門的批准以及獲得醫生和患者對產品的信任至關重要。

細分市場洞察

產品洞察

2022 年，英夫利西單抗領域主導了生物相似藥單株抗體市場，預計未來幾年將繼續擴大。英夫利西單抗是一種嵌合單株抗體，靶向併中和腫瘤壞死因子-α（TNF-α），這是一種參與發炎反應的細胞激素。英夫利西單抗最初以 Remicade (R) 品牌開發和銷售，已成為治療類風濕關節炎、克隆氏症、牛皮癬和僵直性脊椎炎自體免疫疾病的遊戲規則改變者。

應用洞察

2022 年，腫瘤學領域主導了生物相似藥單株抗體市場，預計未來幾年將繼續擴大。全球癌症負擔一直在穩步增加，推動了對有效且負擔得起的治療方案的需求。生物相似藥單株抗體以更低的成本提供與其原廠產品相當的功效和安全性，從而提供了一個有前景的解決方案。隨著癌症發生率持續飆升，對腫瘤特異性單株抗體生物相似藥的需求勢將不斷增加，使腫瘤學成為該市場的驅動力。

區域洞察

亞太地區擁有多元化的經濟體，每個經濟體都有其獨特的醫療保健挑戰。隨著慢性病和複雜醫療狀況負擔的增加，對有效且負擔得起的治療方案的需求也在成長。生物相似藥單株抗體提供了一種可行的解決方案，使許多患者能夠獲得以前在經濟上無法承受的先進療法。由於注重成本效益，亞洲醫療保健系統擴大轉向生物相似藥，以縮小兩者之間的差距

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球生物相似藥單株抗體市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 副產物（英夫利西單抗、利妥昔單抗、阿昔單抗、曲妥珠單抗、阿達木單抗、貝伐單抗等）
    • 按應用（腫瘤學、慢性病和自體免疫疾病、其他）
    • 按地區
    • 按公司分類（前 5 名市場參與者的股份）
  • 市場地圖
    • 按產品分類
    • 按應用
    • 按地區

第 6 章：北美生物相似藥單株抗體市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 按國家/地區

第 7 章：歐洲生物相似藥單株抗體市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 按國家/地區

第 8 章：亞太地區生物相似藥單株抗體市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按應用
    • 按國家/地區

第 9 章：南美洲生物相似藥單株抗體市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區

第 10 章：中東和非洲生物相似藥單株抗體市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按應用
    • 按國家/地區

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第13章：競爭格局

  • 雅培
  • 輝瑞公司
  • 諾華公司
  • 艾伯維公司
  • 科赫勒斯生物科學公司
  • 百康有限公司
  • 艾爾建公司。
  • 雅閣醫療有限公司。
  • 安進公司
  • 雷迪博士的實驗室

第 14 章：策略建議

第 15 章：關於我們與免責聲明

簡介目錄
Product Code: 15878

The Global biosimilar monoclonal antibodies (mAbs) market, valued at USD 5.22 Billion in 2022, is poised for substantial growth in the forecast period, with a projected CAGR of 11.87% through 2028 and expected to reach USD 10.19 Billion in 2028. The biosimilar monoclonal antibodies (mAbs) market has emerged as a dynamic and transformative sector within the biopharmaceutical industry. Biosimilars, often referred to as "generic" versions of biologic drugs, have gained significant attention for their potential to provide cost-effective alternatives to expensive biologics while maintaining comparable safety and efficacy profiles. In recent years, biosimilar mAbs have made remarkable strides, reshaping the pharmaceutical landscape and opening doors to improved patient access and healthcare affordability. Monoclonal antibodies are a class of biologic drugs designed to target specific proteins, cells, or tissues within the body. They have proven highly effective in treating a wide range of diseases, including cancer, autoimmune disorders, and inflammatory conditions. However, the complex nature of mAbs and the intricate manufacturing processes involved have led to high development costs and subsequently elevated treatment expenses. Biosimilar mAbs, essentially highly similar versions of approved reference mAbs, are developed using recombinant DNA technology and manufactured in living cells. While they may not be identical to the reference product due to inherent variability in biologics, they are designed to be as close as possible in terms of safety, efficacy, and quality. One of the primary drivers is the urgent need for cost containment within healthcare systems worldwide. Biosimilar mAbs offer the potential to significantly reduce healthcare expenditure, as they typically enter the market at a lower price point compared to their reference counterparts, thus augmenting the projected growth of the market.

Key Market Drivers

Rising Cancer and Autoimmune Disorders Driving the Biosimilar Monoclonal Antibodies Market

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.22 Billion
Market Size 2028USD 10.19 Billion
CAGR 2023-202811.87%
Fastest Growing SegmentOncology
Largest MarketAsia Pacific

The healthcare landscape has witnessed a significant surge in the prevalence of cancer and autoimmune disorders, complex and challenging medical conditions affecting millions of individuals worldwide. As the incidence of these conditions continues to rise, the demand for effective and affordable treatments has led to the emergence and expansion of the biosimilar monoclonal antibodies (mAbs) market. This rapidly evolving market segment is playing a pivotal role in addressing the therapeutic needs of patients while offering potential cost savings for healthcare systems. Cancer and autoimmune disorders represent two distinct medical challenges, both characterized by complex mechanisms involving the immune system. Cancer, a group of diseases characterized by uncontrolled cell growth, is one of the leading global causes of death. Autoimmune disorders, on the other hand, result from a misdirected immune response where the body's immune system attacks its own healthy tissues, leading to chronic inflammation and tissue damage. The incidence of both cancer and autoimmune disorders has been steadily increasing over the past few decades, driven by aging populations, environmental exposures, lifestyle changes, and genetic predisposition. Consequently, there's an urgent need for innovative and effective therapies to treat these conditions and improve patients' quality of life. The biosimilar monoclonal antibodies market has rapidly grown due to the increasing demand for more affordable treatment options for cancer and autoimmune disorders. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines and pathways for biosimilar approval, ensuring rigorous evaluation of their safety and efficacy.

Rising Regulatory Support Driving the Biosimilar Monoclonal Antibodies Market

To address concerns about the safety, efficacy, and quality of biosimilar monoclonal antibodies, regulatory agencies worldwide have developed comprehensive guidelines and frameworks. These guidelines outline the rigorous scientific and clinical evaluation processes biosimilar products must undergo before approval for market entry. The goal is to ensure patients and healthcare professionals can trust the equivalence of biosimilars to their reference products. For example, both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have released guidelines addressing biosimilar monoclonal antibodies. These guidelines emphasize extensive comparative analytical studies, including physicochemical and functional characterization, as well as non-clinical and clinical studies to demonstrate equivalence to the reference product. As more originator monoclonal antibody patents expire, the market is ripe for biosimilar alternatives. This creates opportunities for manufacturers to enter the market and offer alternatives at competitive prices. The rigorous regulatory pathways and guidelines set by agencies like the EMA and FDA have instilled confidence in healthcare professionals and patients regarding the safety and efficacy of biosimilar monoclonal antibodies.

Key Market Challenges

Manufacturing Complexity

The manufacturing process for biosimilar mAbs is intricate and involves living cells, which can result in product variability. Maintaining consistent quality and comparability to the reference product is a significant challenge.

Clinical Trials and Data Requirements

Generating clinical trial data demonstrating similarity in safety and efficacy between a biosimilar and its reference mAb is essential for regulatory approval. Designing these trials and ensuring patient recruitment can be complex and resource-intensive.

Market Competition

As more companies enter the biosimilar mAbs market, competition intensifies. Pricing strategies, market access, and differentiation become critical factors for success.

Key Market Trends

Technological Advancements

The pharmaceutical industry has experienced a seismic shift in recent years, driven by remarkable advancements in biotechnology and innovative research methodologies. Among the significant breakthroughs, biosimilar monoclonal antibodies (mAbs) have emerged as a potent force shaping the medical landscape. These cutting-edge therapeutic agents are revolutionizing the treatment of various diseases, ranging from cancer to autoimmune disorders. The rapid growth of the biosimilar mAbs market is intricately intertwined with the continual progress in technology and innovation. Advancements in technology have enabled a deeper understanding of disease mechanisms and patient variability. This has paved the way for the concept of precision medicine, where treatments are tailored to individual patients based on their genetic makeup, disease characteristics, and response to therapy. Biosimilar mAbs hold immense promise in this regard, as they can be developed to target specific disease pathways with greater precision. This approach not only enhances therapeutic outcomes but also minimizes side effects, thereby improving patient quality of life. One of the key drivers behind the biosimilar mAbs market's growth is the continual evolution of bioprocessing and manufacturing technologies. Innovations in cell culture techniques, purification processes, and bioreactor designs have enabled manufacturers to produce biosimilar mAbs with higher purity and yield. This not only ensures the safety of the end product but also reduces production costs, making these therapies more economically viable for patients and healthcare systems. Accurate characterization and comparison of biosimilar mAbs with their reference products are critical to ensuring their safety and efficacy. Technological advancements in analytical techniques, such as mass spectrometry, nuclear magnetic resonance, and high-performance liquid chromatography, have made it possible to comprehensively assess the structural and functional similarities between biosimilars and reference mAbs. This level of detail is essential for regulatory approval and gaining physicians' and patients' trust in the product.

Segmental Insights

Product Insights

In 2022, the Infliximab segment dominated the Biosimilar Monoclonal Antibodies market and is predicted to continue expanding in the coming years. Infliximab is a chimeric monoclonal antibody that targets and neutralizes tumor necrosis factor-alpha (TNF-α), a cytokine involved in the inflammatory response. Originally developed and marketed under the brand name Remicade®, infliximab has been a game-changer in treating autoimmune diseases like rheumatoid arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis.

Application Insights

In 2022, the Oncology segment dominated the Biosimilar Monoclonal Antibodies market and is predicted to continue expanding in the coming years. The global burden of cancer has been steadily increasing, driving the demand for effective and affordable treatment options. Biosimilar mAbs offer a promising solution by providing comparable efficacy and safety to their originator counterparts at a lower cost. As cancer incidence continues to surge, the demand for oncology-specific biosimilar mAbs is poised to escalate, making oncology a driving force in this market.

Regional Insights

The Asia-Pacific region hosts a diverse range of economies, each with its unique healthcare challenges. As the burden of chronic diseases and complex medical conditions increases, the demand for effective and affordable treatment options has grown. Biosimilar monoclonal antibodies offer a viable solution, providing access to advanced therapies that were previously financially out of reach for many patients. With a focus on cost-effectiveness, Asian healthcare systems are increasingly turning to biosimilars to bridge the gap between

Key Market Players

  • Abbott
  • Pfizer
  • Novartis AG
  • AbbVie, Inc.
  • Coherus BioSciences
  • Biocon Limited
  • Allergan plc.
  • Accord Healthcare limited.
  • Amgen inc.
  • Dr. Reddy's Laboratory

Report Scope:

  • In this report, the Global Biosimilar Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Monoclonal Antibodies Market, By Product:

  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
  • Other

Biosimilar Monoclonal Antibodies Market, By Application:

  • Oncology
  • Chronic & Autoimmune Diseases
  • Others

Biosimilar Monoclonal Antibodies Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Biosimilar Monoclonal Antibodies Market.

Available Customizations:

  • Global Biosimilar Monoclonal Antibodies Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilar Monoclonal Antibodies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab and Other)
    • 5.2.2. By Application (Oncology, Chronic & Autoimmune Diseases, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Application
    • 5.3.3. By Region

6. North America Biosimilar Monoclonal Antibodies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
      • 6.2.3.1. United States Biosimilar Monoclonal Antibodies Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
        • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
        • 6.2.3.1.2.1. By Product
        • 6.2.3.1.2.2. By Application
      • 6.2.3.2. Canada Biosimilar Monoclonal Antibodies Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
        • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
        • 6.2.3.2.2.1. By Product
        • 6.2.3.2.2.2. By Application
      • 6.2.3.3. Mexico Biosimilar Monoclonal Antibodies Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
        • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
        • 6.2.3.3.2.1. By Test
        • 6.2.3.3.2.2. By Application

7. Europe Biosimilar Monoclonal Antibodies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2.
    • 7.2.3. By Application
    • 7.2.4. By Country
      • 7.2.4.1. France Biosimilar Monoclonal Antibodies Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Application
      • 7.2.4.2. Germany Biosimilar Monoclonal Antibodies Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Application
      • 7.2.4.3. United Kingdom Biosimilar Monoclonal Antibodies Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Application
      • 7.2.4.4. Italy Biosimilar Monoclonal Antibodies Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Application
      • 7.2.4.5. Spain Biosimilar Monoclonal Antibodies Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Application

8. Asia Pacific Biosimilar Monoclonal Antibodies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
      • 8.2.3.1. China Biosimilar Monoclonal Antibodies Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
        • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
        • 8.2.3.1.2.1. By Product
        • 8.2.3.1.2.2. By Application
      • 8.2.3.2. India Biosimilar Monoclonal Antibodies Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
        • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
        • 8.2.3.2.2.1. By Product
        • 8.2.3.2.2.2. By Application
      • 8.2.3.3. South Korea Biosimilar Monoclonal Antibodies Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
        • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
        • 8.2.3.3.2.1. By Product
        • 8.2.3.3.2.2. By Application
      • 8.2.3.4. Japan Biosimilar Monoclonal Antibodies Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
        • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
        • 8.2.3.4.2.1. By Product
        • 8.2.3.4.2.2. By Application
      • 8.2.3.5. Australia Biosimilar Monoclonal Antibodies Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
        • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
        • 8.2.3.5.2.1. By Product
        • 8.2.3.5.2.2. By Application

9. South America Biosimilar Monoclonal Antibodies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2.
    • 9.2.3. By Application
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Biosimilar Monoclonal Antibodies Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Application
      • 9.2.4.2. Argentina Biosimilar Monoclonal Antibodies Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Application
      • 9.2.4.3. Colombia Biosimilar Monoclonal Antibodies Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Application

10. Middle East & Africa Biosimilar Monoclonal Antibodies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Biosimilar Monoclonal Antibodies Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
        • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
        • 10.2.3.1.2.1. By Product
        • 10.2.3.1.2.2. By Application
      • 10.2.3.2. Saudi Arabia Biosimilar Monoclonal Antibodies Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
        • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
        • 10.2.3.2.2.1. By Product
        • 10.2.3.2.2.2. By Application
      • 10.2.3.3. UAE Biosimilar Monoclonal Antibodies Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
        • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
        • 10.2.3.3.2.1. By Product
        • 10.2.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Abbott
  • 13.2. Pfizer
  • 13.3. Novartis AG
  • 13.4. AbbVie, Inc.
  • 13.5. Coherus BioSciences
  • 13.6. Biocon Limited
  • 13.7. Allergan plc.
  • 13.8. Accord Healthcare limited.
  • 13.9. Amgen inc.
  • 13.10. Dr. Reddy's Laboratory

14. Strategic Recommendations

15. About us & Disclaimer